Japan Prescription drugs: key facts

Last updated 2026-11-11 · 31 sourced answers from KIRA RESEARCH reports and field research. Every figure shows its year and source.

Market size

How big is Japan's prescription drug market?

Japan's prescription drug market reached a record ¥11.8 tn at NHI prices in FY2025, up 3.1%, according to KIRA's 2026 trends and outlook [IQVIA May 2026].

Source: IQVIA May 2026, 2025 · KIRA report: Japan prescription drugs 2026: trends and outlook

Growth

What is the outlook for Japan's prescription drug market to FY2030?

KIRA estimates Japan's FY2030 prescription drug market at ¥11.0-13.6 tn, with ¥11-13 tn as the planning range, against an industry baseline of ¥11.9 tn, according to KIRA's 2026 trends and outlook.

Source: Kira estimates, 2030 · KIRA report: Japan prescription drugs 2026: trends and outlook

How big could Japan's prescription drug market be in FY2030 in KIRA's open-market future?

In KIRA's open-market future for FY2030 (a scenario, not a forecast), the prescription drug market reaches about ¥13.1 tn at the midpoint of the range, according to KIRA's 2026 trends and outlook.

Source: Kira estimates, 2030 · KIRA report: Japan prescription drugs 2026: trends and outlook

Key players

How mature are Japan's local pharma players in AI?

In KIRA's October 2026 outside-in maturity scores, Astellas scores 5 of 5 on models in production, while mid-size generic makers score 1, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

Which Japanese integrators work with AI drug developers?

Fujitsu works with Medipal and THERS, and SoftBank works with Chugai, and both own the buyer relationship and the contract, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

Which generic drug makers in Japan are consolidating?

Sawai and Nichi-Iko agreed in September 2025 to consolidate 15 ingredients between them, one of several generic realignments, according to KIRA's 2026 trends and outlook [Jiho generics 2025].

Source: Jiho generics 2025, 2025 · KIRA report: Japan prescription drugs 2026: trends and outlook

Channels and distribution

What share of hospitals in Japan issue e-prescriptions?

Only 19.4% of hospitals with online eligibility checks issued e-prescriptions in March 2026, up from 13.4% in June 2025, according to KIRA's 2026 AI impact and use cases [Digital Agency 2026].

Source: Digital Agency 2026, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How many pharmacies in Japan could use AI record drafting?

Japan had 63,203 pharmacies at end-FY2024, and Ain plans to roll out record drafting to about 1,300 by April 2027, according to KIRA's 2026 AI impact and use cases [CREX 2026]; [Ain 2026].

Source: CREX 2026, 2024 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

Pricing

How much of Japan's off-patent product range has been cut in price?

95% of off-patent biologic products had their price cut in FY2026, against 69% of small molecules, according to KIRA's 2026 trends and outlook [GlobalData 2026].

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook

How wide is the gap between list price and purchase price for drugs in Japan?

The average gap between list and purchase price fell from 7% in FY2023 to 4.8% in FY2026, according to KIRA's 2026 trends and outlook [Jiho Dec 2025].

Source: Jiho Dec 2025, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook

How many items were repriced or kept price in the April 2026 revision?

In the April 2026 revision, 653 new drugs kept their price and 704 unprofitable products were repriced up, according to KIRA's 2026 trends and outlook [Jiho 2026].

Source: Jiho 2026, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook

Margins

What is the operating margin of pharmaceutical wholesalers in Japan?

The operating margin of pharmaceutical wholesalers was 1.04% in FY2025 (flash), down from 1.11% in FY2024, according to KIRA's 2026 trends and outlook [Jiho wholesale 2026].

Source: Jiho wholesale 2026, 2025 · KIRA report: Japan prescription drugs 2026: trends and outlook

How much do pharmacies earn from drugs and dispensing fees in Japan?

Pharmacies earned ¥6.06 tn from drugs and ¥2.33 tn from dispensing fees, while the gap between list and purchase price is about 5% on average, according to KIRA's 2026 trends and outlook [MHLW 2025 dispensing].

Source: MHLW 2025 dispensing, 2025 · KIRA report: Japan prescription drugs 2026: trends and outlook

Customers and demand

Which OTC-like drugs in Japan face an extra patient charge?

Patients will pay an extra charge on 77 OTC-like ingredients, about ¥90 bn a year, according to KIRA's 2026 trends and outlook [Jiho OTC 2026].

Source: Jiho OTC 2026, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook

Regulation

What did Japan's amended pharmaceutical law change for pharmacies?

The amended PMD Act, in force from May 2025, allows pharmacies to outsource some dispensing work, which favours large chains and central fill, according to KIRA's 2026 AI impact and use cases [PMD Act 2025].

Source: PMD Act 2025, 2025 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How many AI medical software programs are approved in Japan?

45 AI medical programs were approved in Japan out of 296 medical software approvals to March 2025, none of them generative, according to KIRA's 2026 AI impact and use cases [MHLW SaMD 2025].

Source: MHLW SaMD 2025, 2025 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

When did Japan pass the AI Promotion Act?

Japan's AI Promotion Act passed on 28 May 2025; it promotes AI and has no penalties, so sector rules govern, according to KIRA's 2026 AI impact and use cases [AI Act JP 2025].

Source: AI Act JP 2025, 2025 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How many new molecular entities approved in the US or EU are missing in Japan?

143 new molecular entities approved in the US or EU in 2016-20 were still unapproved in Japan, and 86 of them had no Japanese development, according to KIRA's 2026 trends and outlook [PMDA 2023].

Source: PMDA 2023, 2023 · KIRA report: Japan prescription drugs 2026: trends and outlook

Market entry

How should a foreign company enter AI-led work in Japanese prescription drugs?

KIRA ranks a drafting and programming module sold inside an integrator or CRO first by speed to revenue, with the first proof a time saved on one past report against a control, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How much of Japan's drug pipeline is run by foreign firms?

Foreign firms run 73% of Japan's drug pipeline, according to KIRA's 2026 trends and outlook [PhRMA Apr 2026].

Source: PhRMA Apr 2026, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook

How many products have used Japan's rapid-introduction premium?

Only 7 products had used the rapid-introduction premium by 2026, against 28 new drug-loss items, according to KIRA's 2026 trends and outlook [ISPOR 2026].

Source: ISPOR 2026, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook

Investment

How much value could AI create in Japan's prescription drug industry by 2030?

KIRA estimates the largest value pools in Japan's prescription drug industry at JPY 50-120 bn a year for MR and medical work and JPY 40-100 bn for pharmacy records by 2030, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2030 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

Risks

How many prescription drug items were on limited shipment or suspended in Japan?

About 12% of listed prescription drug items were on limited shipment or suspended in August 2026, according to KIRA's 2026 trends and outlook [MHLW 2026 supply].

Source: MHLW 2026 supply, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook

What is the top risk of AI in Japanese drug documents?

Wrong content in a regulated document is rated likelihood 3 and impact 5 of 5, the highest-impact risk on KIRA's list, mitigated by reviewer sign-off and logged edits, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

What did Chugai drop from its antibody design work?

Chugai dropped BRY10, its only clinical antibody designed with its own AI tooling, in 2026, which shows discovery and patient data still stall, according to KIRA's 2026 AI impact and use cases [Fierce 2026].

Source: Fierce 2026, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How the trade works

Which AI use cases in Japanese prescription drugs are ready to act on now?

Four use cases are ready now in Japanese prescription drugs: clinical study report and protocol drafting, trial statistical programming, pharmacy medication-history drafting and MR visit preparation, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

Which AI use cases in Japan need a pilot before they scale?

Four use cases need a pilot first in Japan: demand forecasting and warehouse picking, trial patient finding, safety case intake and patient finding for disease awareness, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How much did clinical study report drafting time fall in Japan?

Clinical study report drafting fell from 120 to 78 working days at the National Cancer Center Hospital, according to KIRA's 2026 AI impact and use cases [MHLW grant 2025].

Source: MHLW grant 2025, 2025 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How much time has automation saved in drug development cases in Japan?

Owner-disclosed savings from live cases in Japan include about 70% less time from hit to drug candidate, for successful cases only [Astellas 2024], and 35% less time on clinical study report drafting, according to KIRA's 2026 AI impact and use cases.

Source: Astellas 2024, 2024 · KIRA report: Japan prescription drugs 2026: AI impact and use cases